Tag: Endless RNA
-
J&J Takes a Profit Hit to Secure an In Vivo CAR-T Platform
Johnson & Johnson accepted near-term earnings pressure to secure access to Sail Biomedicines’ in vivo CAR-T platform, placing a major bet on scalable cell-therapy delivery.